Low-dose italy clonidine administration in the treatment of mild or moderate essential hypertension

Results from a double-blind placebo-controlled study (clobass)

G. Mancia, A. Zanchetti, G. Alunni, R. Buoninconti, V. Casorelli, E. Ciardi, A. Circo, D. Comi, C. De Maestri, A. L. Ferrara, C. Forattini, M. P. Giordano, G. Lavezzaro, A. Lechi, L. Lucentini, A. Maggia, G. Marenco, V. Marigliano, E. Martinengo, C. Mazzola & 16 others D. Mereu, R. Mori, M. Palleschi, G. B. Perroni, F. Plastina, M. Sasdelli, L. Scapellato, M. Timio, A. Tomasi, F. Valagussa, M. Varricchio, L. Viglino, G. Del Re, M. Del Vita, L. Visani, A. Bissanti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Five hundred and fifty-nine hypertensive outpatients with diastolic blood pressure between 95 and 110 mmHg participated in this double-blind, placebo-controlled, multicenter study. Eligible subjects were randomly allocated to receive either clonidine (75 μg twice daily) or a placebo. After 4 weeks, ‘responders’ to treatment (diastolic blood pressure reduced to ≤90mmHg or by ≥10 mmHg) were kept on monotherapy and checked at 4-weekly intervals for another 3 months. Non-responders were given 15 mg chlorthalidone and were also checked for a further 3 months. At the end of the first month, 54.2% of the subjects were responders to clonidine and 41.5% were responders to the placebo (P <0.05 for both groups). Of the remaining patients, 69.0% became responders to clonidine plus chlorthalidone, whereas only 34.7% were responders to placebo plus chlorthalidone (P <0.01 for both groups). Withdrawals from the study because of excessive diastolic blood pressure levels were about eight times less frequent among the subjects treated with clonidine, either alone or with chlorthalidone. Dry mouth was twice as frequent in the clonidine-treated patients, but there was no significant difference in the incidence of all side effects or the number of withdrawals from the study because of side effects between the two groups. We conclude that low-dose clonidine is effective in the treatment of mild or moderate hypertension. Clonidine-related side effects are still evident, but the overall tolerance profile for this reduced dosage of the drug appears to be favorable.

Original languageEnglish
Pages (from-to)539-546
Number of pages8
JournalJournal of Hypertension
Volume8
Issue number6
Publication statusPublished - 1990

Fingerprint

Clonidine
Italy
Chlorthalidone
Placebos
Blood Pressure
Therapeutics
Essential Hypertension
Multicenter Studies
Mouth
Outpatients
Hypertension
Incidence
Pharmaceutical Preparations

Keywords

  • Chlorthalidone
  • Clonidine
  • Essential hypertension
  • Placebo

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Endocrinology

Cite this

Mancia, G., Zanchetti, A., Alunni, G., Buoninconti, R., Casorelli, V., Ciardi, E., ... Bissanti, A. (1990). Low-dose italy clonidine administration in the treatment of mild or moderate essential hypertension: Results from a double-blind placebo-controlled study (clobass). Journal of Hypertension, 8(6), 539-546.

Low-dose italy clonidine administration in the treatment of mild or moderate essential hypertension : Results from a double-blind placebo-controlled study (clobass). / Mancia, G.; Zanchetti, A.; Alunni, G.; Buoninconti, R.; Casorelli, V.; Ciardi, E.; Circo, A.; Comi, D.; Maestri, C. De; Ferrara, A. L.; Forattini, C.; Giordano, M. P.; Lavezzaro, G.; Lechi, A.; Lucentini, L.; Maggia, A.; Marenco, G.; Marigliano, V.; Martinengo, E.; Mazzola, C.; Mereu, D.; Mori, R.; Palleschi, M.; Perroni, G. B.; Plastina, F.; Sasdelli, M.; Scapellato, L.; Timio, M.; Tomasi, A.; Valagussa, F.; Varricchio, M.; Viglino, L.; Re, G. Del; Vita, M. Del; Visani, L.; Bissanti, A.

In: Journal of Hypertension, Vol. 8, No. 6, 1990, p. 539-546.

Research output: Contribution to journalArticle

Mancia, G, Zanchetti, A, Alunni, G, Buoninconti, R, Casorelli, V, Ciardi, E, Circo, A, Comi, D, Maestri, CD, Ferrara, AL, Forattini, C, Giordano, MP, Lavezzaro, G, Lechi, A, Lucentini, L, Maggia, A, Marenco, G, Marigliano, V, Martinengo, E, Mazzola, C, Mereu, D, Mori, R, Palleschi, M, Perroni, GB, Plastina, F, Sasdelli, M, Scapellato, L, Timio, M, Tomasi, A, Valagussa, F, Varricchio, M, Viglino, L, Re, GD, Vita, MD, Visani, L & Bissanti, A 1990, 'Low-dose italy clonidine administration in the treatment of mild or moderate essential hypertension: Results from a double-blind placebo-controlled study (clobass)', Journal of Hypertension, vol. 8, no. 6, pp. 539-546.
Mancia, G. ; Zanchetti, A. ; Alunni, G. ; Buoninconti, R. ; Casorelli, V. ; Ciardi, E. ; Circo, A. ; Comi, D. ; Maestri, C. De ; Ferrara, A. L. ; Forattini, C. ; Giordano, M. P. ; Lavezzaro, G. ; Lechi, A. ; Lucentini, L. ; Maggia, A. ; Marenco, G. ; Marigliano, V. ; Martinengo, E. ; Mazzola, C. ; Mereu, D. ; Mori, R. ; Palleschi, M. ; Perroni, G. B. ; Plastina, F. ; Sasdelli, M. ; Scapellato, L. ; Timio, M. ; Tomasi, A. ; Valagussa, F. ; Varricchio, M. ; Viglino, L. ; Re, G. Del ; Vita, M. Del ; Visani, L. ; Bissanti, A. / Low-dose italy clonidine administration in the treatment of mild or moderate essential hypertension : Results from a double-blind placebo-controlled study (clobass). In: Journal of Hypertension. 1990 ; Vol. 8, No. 6. pp. 539-546.
@article{b3b905e37a7c493c87a9d6bc6acaf47c,
title = "Low-dose italy clonidine administration in the treatment of mild or moderate essential hypertension: Results from a double-blind placebo-controlled study (clobass)",
abstract = "Five hundred and fifty-nine hypertensive outpatients with diastolic blood pressure between 95 and 110 mmHg participated in this double-blind, placebo-controlled, multicenter study. Eligible subjects were randomly allocated to receive either clonidine (75 μg twice daily) or a placebo. After 4 weeks, ‘responders’ to treatment (diastolic blood pressure reduced to ≤90mmHg or by ≥10 mmHg) were kept on monotherapy and checked at 4-weekly intervals for another 3 months. Non-responders were given 15 mg chlorthalidone and were also checked for a further 3 months. At the end of the first month, 54.2{\%} of the subjects were responders to clonidine and 41.5{\%} were responders to the placebo (P <0.05 for both groups). Of the remaining patients, 69.0{\%} became responders to clonidine plus chlorthalidone, whereas only 34.7{\%} were responders to placebo plus chlorthalidone (P <0.01 for both groups). Withdrawals from the study because of excessive diastolic blood pressure levels were about eight times less frequent among the subjects treated with clonidine, either alone or with chlorthalidone. Dry mouth was twice as frequent in the clonidine-treated patients, but there was no significant difference in the incidence of all side effects or the number of withdrawals from the study because of side effects between the two groups. We conclude that low-dose clonidine is effective in the treatment of mild or moderate hypertension. Clonidine-related side effects are still evident, but the overall tolerance profile for this reduced dosage of the drug appears to be favorable.",
keywords = "Chlorthalidone, Clonidine, Essential hypertension, Placebo",
author = "G. Mancia and A. Zanchetti and G. Alunni and R. Buoninconti and V. Casorelli and E. Ciardi and A. Circo and D. Comi and Maestri, {C. De} and Ferrara, {A. L.} and C. Forattini and Giordano, {M. P.} and G. Lavezzaro and A. Lechi and L. Lucentini and A. Maggia and G. Marenco and V. Marigliano and E. Martinengo and C. Mazzola and D. Mereu and R. Mori and M. Palleschi and Perroni, {G. B.} and F. Plastina and M. Sasdelli and L. Scapellato and M. Timio and A. Tomasi and F. Valagussa and M. Varricchio and L. Viglino and Re, {G. Del} and Vita, {M. Del} and L. Visani and A. Bissanti",
year = "1990",
language = "English",
volume = "8",
pages = "539--546",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Low-dose italy clonidine administration in the treatment of mild or moderate essential hypertension

T2 - Results from a double-blind placebo-controlled study (clobass)

AU - Mancia, G.

AU - Zanchetti, A.

AU - Alunni, G.

AU - Buoninconti, R.

AU - Casorelli, V.

AU - Ciardi, E.

AU - Circo, A.

AU - Comi, D.

AU - Maestri, C. De

AU - Ferrara, A. L.

AU - Forattini, C.

AU - Giordano, M. P.

AU - Lavezzaro, G.

AU - Lechi, A.

AU - Lucentini, L.

AU - Maggia, A.

AU - Marenco, G.

AU - Marigliano, V.

AU - Martinengo, E.

AU - Mazzola, C.

AU - Mereu, D.

AU - Mori, R.

AU - Palleschi, M.

AU - Perroni, G. B.

AU - Plastina, F.

AU - Sasdelli, M.

AU - Scapellato, L.

AU - Timio, M.

AU - Tomasi, A.

AU - Valagussa, F.

AU - Varricchio, M.

AU - Viglino, L.

AU - Re, G. Del

AU - Vita, M. Del

AU - Visani, L.

AU - Bissanti, A.

PY - 1990

Y1 - 1990

N2 - Five hundred and fifty-nine hypertensive outpatients with diastolic blood pressure between 95 and 110 mmHg participated in this double-blind, placebo-controlled, multicenter study. Eligible subjects were randomly allocated to receive either clonidine (75 μg twice daily) or a placebo. After 4 weeks, ‘responders’ to treatment (diastolic blood pressure reduced to ≤90mmHg or by ≥10 mmHg) were kept on monotherapy and checked at 4-weekly intervals for another 3 months. Non-responders were given 15 mg chlorthalidone and were also checked for a further 3 months. At the end of the first month, 54.2% of the subjects were responders to clonidine and 41.5% were responders to the placebo (P <0.05 for both groups). Of the remaining patients, 69.0% became responders to clonidine plus chlorthalidone, whereas only 34.7% were responders to placebo plus chlorthalidone (P <0.01 for both groups). Withdrawals from the study because of excessive diastolic blood pressure levels were about eight times less frequent among the subjects treated with clonidine, either alone or with chlorthalidone. Dry mouth was twice as frequent in the clonidine-treated patients, but there was no significant difference in the incidence of all side effects or the number of withdrawals from the study because of side effects between the two groups. We conclude that low-dose clonidine is effective in the treatment of mild or moderate hypertension. Clonidine-related side effects are still evident, but the overall tolerance profile for this reduced dosage of the drug appears to be favorable.

AB - Five hundred and fifty-nine hypertensive outpatients with diastolic blood pressure between 95 and 110 mmHg participated in this double-blind, placebo-controlled, multicenter study. Eligible subjects were randomly allocated to receive either clonidine (75 μg twice daily) or a placebo. After 4 weeks, ‘responders’ to treatment (diastolic blood pressure reduced to ≤90mmHg or by ≥10 mmHg) were kept on monotherapy and checked at 4-weekly intervals for another 3 months. Non-responders were given 15 mg chlorthalidone and were also checked for a further 3 months. At the end of the first month, 54.2% of the subjects were responders to clonidine and 41.5% were responders to the placebo (P <0.05 for both groups). Of the remaining patients, 69.0% became responders to clonidine plus chlorthalidone, whereas only 34.7% were responders to placebo plus chlorthalidone (P <0.01 for both groups). Withdrawals from the study because of excessive diastolic blood pressure levels were about eight times less frequent among the subjects treated with clonidine, either alone or with chlorthalidone. Dry mouth was twice as frequent in the clonidine-treated patients, but there was no significant difference in the incidence of all side effects or the number of withdrawals from the study because of side effects between the two groups. We conclude that low-dose clonidine is effective in the treatment of mild or moderate hypertension. Clonidine-related side effects are still evident, but the overall tolerance profile for this reduced dosage of the drug appears to be favorable.

KW - Chlorthalidone

KW - Clonidine

KW - Essential hypertension

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=0025146241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025146241&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 539

EP - 546

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 6

ER -